Literature DB >> 25447311

Coagulation factor VII is regulated by androgen receptor in breast cancer.

Ali Naderi1.   

Abstract

Androgen receptor (AR) is widely expressed in breast cancer; however, there is limited information on the key molecular functions and gene targets of AR in this disease. In this study, gene expression data from a cohort of 52 breast cancer cell lines was analyzed to identify a network of AR co-expressed genes. A total of 300 genes, which were significantly enriched for cell cycle and metabolic functions, showed absolute correlation coefficients (|CC|) of more than 0.5 with AR expression across the dataset. In this network, a subset of 35 "AR-signature" genes were highly co-expressed with AR (|CC|>0.6) that included transcriptional regulators PATZ1, NFATC4, and SPDEF. Furthermore, gene encoding coagulation factor VII (F7) demonstrated the closest expression pattern with AR (CC=0.716) in the dataset and factor VII protein expression was significantly associated to that of AR in a cohort of 209 breast tumors. Moreover, functional studies demonstrated that AR activation results in the induction of factor VII expression at both transcript and protein levels and AR directly binds to a proximal region of F7 promoter in breast cancer cells. Importantly, AR activation in breast cancer cells induced endogenous factor VII activity to convert factor X to Xa in conjunction with tissue factor. In summary, F7 is a novel AR target gene and AR activation regulates the ectopic expression and activity of factor VII in breast cancer cells. These findings have functional implications in the pathobiology of thromboembolic events and regulation of factor VII/tissue factor signaling in breast cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen receptor; Breast cancer; Factor VII; Gene transcription

Mesh:

Substances:

Year:  2014        PMID: 25447311      PMCID: PMC4302010          DOI: 10.1016/j.yexcr.2014.10.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

Review 1.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

Review 2.  Recent knowledge of NFATc4 in oncogenesis and cancer prognosis.

Authors:  Qiu-Hua Zhong; Si-Wei Zha; Andy T Y Lau; Yan-Ming Xu
Journal:  Cancer Cell Int       Date:  2022-06-13       Impact factor: 6.429

3.  Pleiotropic effects of n-6 and n-3 fatty acid-related genetic variants on circulating hemostatic variables.

Authors:  Lu-Chen Weng; Weihua Guan; Lyn M Steffen; James S Pankow; Nathan Pankratz; Ming-Huei Chen; Mary Cushman; Saonli Basu; Aaron R Folsom; Weihong Tang
Journal:  Thromb Res       Date:  2018-06-01       Impact factor: 3.944

Review 4.  Targeting clotting proteins in cancer therapy - progress and challenges.

Authors:  Wolfram Ruf; Andrea S Rothmeier; Claudine Graf
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

5.  C1orf64 is a novel androgen receptor target gene and coregulator that interacts with 14-3-3 protein in breast cancer.

Authors:  Ali Naderi
Journal:  Oncotarget       Date:  2017-05-11

6.  SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies.

Authors:  Ali Naderi
Journal:  Mol Oncol       Date:  2018-04-16       Impact factor: 6.603

7.  Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray.

Authors:  Ali Mohamed Alshabi; Ibrahim Ahmed Shaikh; Chanabasayya Vastrad
Journal:  Biomolecules       Date:  2019-07-15

8.  A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.

Authors:  Hongjuan Zhao; John T Leppert; Donna M Peehl
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.